ICER Study On Coverage 'Fairness' Could Inform Manufacturer Pricing vs Benefit Design Debate
Study will look at prior authorization, step therapy and required medication switching for drugs considered to be reasonably priced.
You may also be interested in...
Institute for Clinical and Economic Review analysis of whether payers are providing ‘fair access’ to fairly priced drugs was hampered by a lack of transparency among payers, leading to calls for reform.
Step Therapy: As Bill Aims To Routinize Processes, Study Finds Policies Often Stricter Than Clinical Guidelines
Chronic migraine and anti-inflammatory treatments were most often subject to step therapy, Tufts researchers found. Policies varied from payer to payer, raising concerns over the impact of shifting requirements for treating the same disease as patients move among insurers.
A new pilot program by the insurer is offering a $500 debit card to patients who switch from the blockbuster Novartis psoriasis drug to Lilly's rival Taltz or other preferred drugs.